Drug-eluting stents are associated with significant reductions in target vessel revascularization at long-term follow-up as compared with bare metal stents implanted in patients with STEMI undergoing primary percutaneous coronary intervention, according to results of a meta-analysis.
Occlutech GmbH, the leading European developer of minimally invasive implants for the treatment of structural heart disease, today announced receiving a favourable Supreme Court ruling from The Hague in The Netherlands in the on-going patent litigation with AGA/St Jude Medical. A first instance court ruling obtained in favour of Occlutech had been appealed by AGA in 2008, as had the favourable appeal court decision obtained in 2010.
Silver Spring, MD - More studies of atrial septal defect (ASD) occluders are needed to better understand the incidence and causes of rare life-threatening adverse events related to the devices, an FDA advisory panel concluded at its May 24 meeting.
According to study results to be featured in Sunday’s late-breaking clinical trials session at the American Association of Clinical Endocrinologists (AACE) 21st Annual Scientific and Clinical Congress in Philadelphia, the Resolute® drug-eluting stent (DES) from Medtronic, Inc. (NYSE:MDT) yields strong performance in coronary artery disease (CAD) patients both with and without diabetes through two years of follow-up.
Results of ADVANCE―a US clinical trial evaluating the use of the HeartWare Ventricular Assist System (HeartWare International) as a bridge to heart transplantation in patients with advanced heart failure―were published on 22 May ahead of print in Circulation. Data demonstrate the potential utility of the HVAD Pump to improve treatment outcomes for end-stage heart failure patients.
Un estudio realizado en Estados Unidos revela que uno de cada siete pacientes tratados con una angioplastia programada para eliminar una obstrucción en las arterias cardíacas no reunía los criterios para realizar la cirugía. Los investigadores señalaron que, de acuerdo con las guías, la indicación sería incierta en la mitad de los pacientes.
Balloon expansion of drug-eluting stents can result in polymer surface damage and microparticle detachment, which may contribute to DES-related adverse events, including stent thrombosis.
Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced results of a patient-level pooled analysis of six-month clinical outcomes of the TRYTON Side Branch Stent. Findings were presented last week in Paris at EuroPCR, the official congress of the European Association of Percutaneous Cardiovascular Interventions.
La hipertensión arterial (HTA) es el factor de riesgo más importante a la hora de desarrollar enfermedades cardiovasculares como el infarto de miocardio, el ictus, la insuficiencia renal o arritmias cardiacas, informa el Doctor García Donaire, especialista en riesgo cardiovascular en el Hospital USP San Camilo de Madrid. Asimismo, se relaciona con un peor pronóstico cuando se asocia a cualquier otra patología.
A novel percutaneous device for mitral valve regurgitation helps get failing hearts back in shape and eases symptoms, early-phase results showed. The device, which pushes the mitral valve leaflets closer together from inside the adjacent coronary sinus, reduced left ventricular systolic and diastolic volume at 12 months (both P=0.015), David G. Reuter, MD, PhD, of Seattle Children s Hospital and chief medical officer of device maker Cardiac Dimensions, and colleagues found.
Ralph Toelg, Segeberger Heart Center Clinic, Germany, and Thomas Schmitz, Elisabeth Hospital, presented at EuroPCR 2012 six-month results from the DELUX registry which demonstrated positive safety and efficacy outcomes for the Pantera Lux Paclitaxel Releasing Balloon (Biotronik) in more than 1000 patients.
The company reported worldwide fourth quarter revenue of $4.297 billion, compared to the $4.167 billion reported in the fourth quarter of fiscal year 2011, an increase of 4 percent on a constant currency basis after adjusting for a $42 million negative foreign currency impact or 3 percent as reported. As reported, fourth quarter net earnings were $991 million, or $0.94 per diluted share, an increase of 28 percent and 31 percent, respectively, over the same period in the prior year. As detailed in the attached table, fourth quarter net earnings and diluted earnings per share on a non-GAAP basis were $1.036 billion and $0.99, an increase of 7 percent and 10 percent, respectively, over the same period in the prior year.
Volcano Corporation (NASDAQ: VOLC), a worldwide leader in precision guided therapy tools, today provided an overview of data from multiple ground-breaking clinical trials presented last week at the EuroPCR conference, a key international cardiology meeting held in Paris, France.
Boston Scientific Corporation (NYSE: BSX) anuncia los resultados de factibilidad del estudio REPRISE I, en el que se evaluó la seguridad aguda de la válvula aótica Lotus™ en los pacientes con valvulopatía aórtica. La válvula aórtica Lotus es el primer dispositivo de valvuloplastia aórtica transcatéter de su clase que se ha diseñado para minimizar la regurgitación aórtica (escape) y es totalmente reposicionable y extraíble antes de su liberación. Los datos presentados hoy en el congreso EuroPCR en París demuestran el éxito del implante de la válvula en todos los pacientes, con una ausencia prácticamente total de regurgitación paravalvular tras la colocación o en el momento el alta.
A tool incorporating several measures of frailty may improve risk prediction among older patients undergoing transcatheter aortic valve implantation (TAVI) for severe symptomatic aortic valve stenosis, a single-center study showed. A frailty index was associated with both all-cause mortality and major adverse cardiovascular and cerebrovascular events (MACCE) 1 year after the procedure (ORs 3.68 and 4.89, respectively), according to Stephan Windecker, MD, of Bern University Hospital in Switzerland, and colleagues.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos